EMA — authorised 18 July 2014
- Application: EMEA/H/C/002827
- Marketing authorisation holder: Biogen Netherlands B.V.
- Local brand name: Plegridy
- Indication: Treatment of relapsing remitting multiple sclerosis in adult patients.
- Status: approved
🇪🇺 SC Peginterferon beta-1a in European Union
EMA authorised SC Peginterferon beta-1a on 18 July 2014
Marketing authorisation
SC Peginterferon beta-1a in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SC Peginterferon beta-1a approved in European Union?
Yes. EMA authorised it on 18 July 2014.
Who is the marketing authorisation holder for SC Peginterferon beta-1a in European Union?
Biogen Netherlands B.V. holds the EU marketing authorisation.